Palvella Therapeutics Director Buys $500,000 of Stock Amid Upsized Offering and Positive Phase 3 News
A Palvella Therapeutics director bought $500,000 of company stock on February 27, 2026, joining a period of intense corporate activity that included an upsized public offering and a bullish analyst update tied to positive phase 3 data for the company’s QTORIN Rapamycin treatment. The transaction and recent financing highlight simultaneous insider c…